Loading...
•
Mar 31, 2020
CorMedix Q1 2020 Earnings Report
Reported financial results for Q1 2020 and provided a business update.
Key Takeaways
CorMedix reported a net loss of $5.6 million, or $0.21 per share, for the first quarter of 2020. The company's operating expenses increased by $0.7 million, driven by higher SG&A expenses, partially offset by a $0.1 million increase in gross profit on sales. The Company reported cash and short term investments of $23.2 million at March 31, 2020.
Net loss for Q1 2020 was $5.6 million, or $0.21 per share.
Operating expenses increased by $0.7 million, primarily due to higher SG&A expenses.
Cash and short term investments were $23.2 million as of March 31, 2020.
Company maintains guidance for an anticipated decision on approval of the NDA in the second half of 2020.
Forward Guidance
The Company believes that, based on its current cash resources, it has sufficient resources to fund operations into the second quarter of 2021, including initial preparations for commercial launch.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...